Lipid accumulation and transforming growth factor-β upregulation in the kidneys of rats administered angiotensin II

Hypertension

Volumn 46, Issue 5, 2005, Pages 1180-1185

  Saito, Kan ^a   Ishizaka, Nobukazu ^a   Hara, Masumi ^a   Matsuzaki, Gen ^a   Sata, Masataka ^a   Mori, Ichiro ^b   Ohno, Minoru ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Lipids; Transforming growth factors

Indexed keywords

ANGIOTENSIN; DEFEROXAMINE; DYE; FATTY ACID SYNTHASE; IRON; IRON CHELATING AGENT; LIPID; MESSENGER RNA; NORADRENALIN; OIL RED O; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HISTOLOGY; HOMEOSTASIS; IRON HOMEOSTASIS; KIDNEY CORTEX; KIDNEY FAILURE; KIDNEY TUBULE EPITHELIUM; LIPID METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STAINING;

ANGIOTENSIN II; ANIMALS; DEFEROXAMINE; FATTY ACID SYNTHETASE COMPLEX; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; IRON; IRON CHELATING AGENTS; KIDNEY; LIPID METABOLISM; LIPIDS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STAINING AND LABELING; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUPEROXIDES; TISSUE DISTRIBUTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 27444436719     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000184653.75036.d5     Document Type: Article

References (36)

1. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003; 14:281-287.
2. Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53:319-336.
3. Barnes SE, Weinberg PD. Two patterns of lipid deposition in the cholesterol-fed rabbit. Arterioscler Thromb Vasc Biol. 1999;19:2376-2386.
4. Nunnari JJ, Fisher M, White SD. Inhibition of lipid deposition in the hypercholesterolemic rat by clentiazem, a calcium channel blocker. Exp Mol Pathol. 1992;57:193-204.
5. Rogers KA, Karnovsky MJ. A rapid method for the detection of early stages of atherosclerotic lesion formation. Am J Pathol. 1988;133:451-455.
6. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18: 1692-1700.
7. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000;97:1784-1789.
8. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis. 2004;24:399-413.
9. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2:1309-1311.
10. Ishizaka N, Aizawa T, Yamazaki I, Usui S, Mori I, Kurokawa K, Tang SS, Ingelfinger JR, Ohno M, Nagai R. Abnormal iron deposition in renal cells in the rat with chronic angiotensin II administration. Lab Invest. 2002;82:87-96.
11. Saito K, Ishizaka N, Aizawa T, Sata M, Iso ON, Noiri E, Ohno M, Nagai R. Role of aberrant iron homeostasis in the upregulation of transforming growth factor-beta1 in the kidney of angiotensin II-induced hypertensive rats. Hypertens Res. 2004;27:599-607.
12. Ishizaka N, de Leon H, Laursen JB, Fukui T, Wilcox JN, De Keulenaer G, Griendling KK, Alexander RW. Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Circulation. 1997; 96:1923-1929.
13. Aizawa T, Ishizaka N, Taguchi J, Nagai R, Mori I, Tang SS, Ingelfinger JR, Ohno M. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension. 2000;35:800-806.
14. Saito K, Ishizaka N, Mitani H, Ohno M, Nagai R. Iron chelation and a free radical scavenger suppress angiotensin II-induced downregulation of klotho, an anti-aging gene, in rat. FEBS Lett. 2003;551:58-62.
15. Fujihara CK, Padilha RM, Zatz R. Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. Diabetes. 1992;41:286-293.
16. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 2000;57:167-182.
17. Chander PN, Gealekman O, Brodsky SV, Elitok S, Tojo A, Crabtree M, Gross SS, Goligorsky MS. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol. 2004; 15:2391-2403.
18. Lee HS, Lee JS, Koh HI, Ko KW. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol. 1991;36:67-75.
19. Dominguez JH, Tang N, Xu W, Evan AP, Siakotos AN, Agarwal R, Walsh J, Deeg M, Pratt JH, March KL, Monnier VM, Weiss MF, Baynes JW, Peterson R. Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int. 2000;57:92-104.
20. Eddy AA. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int. 1996;50:1139-1149.
21. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis. 1995;26:152-161.
22. Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA, Stern J, Jha S, Pigato J, Lemer ML, Poppas DP, Vaughan ED, Felsen D. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int. 2000;58:2301-2313.
23. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol. 2003;14:1816-1824.
24. Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res. 2001;29:270-279.
25. Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res. 2004;27:293-299.
26. Ran J, Hirano T, Adachi M. Chronic Ang II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab. 2004;287:E955-E961.
27. Kim S, Dugail I, Standridge M, Claycombe K, Chun J, Moustaid-Moussa N. Angiotensin II-responsive element is the insulin-responsive element in the adipocyte fatty acid synthase gene: role of adipocyte determination and differentiation factor 1/sterol-regulatory-element-binding protein 1c. Biochem J. 2001;357:899-904.
28. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002;277: 18919-18927.
29. Neuman M, West M, Zimmerman HJ. The relationship between proteinuria and fatty elements in the urine sediment. Am J Med Sci. 1961; 241:617-624.
30. Chatterjee S, Kwiterovich PO Jr, Gupta P, Erozan YS, Alving CR, Richards RL. Localization of urinary lactosylceramide in cytoplasmic vesicles of renal tubular cells in homozygous familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1983;80:1313-1317.
31. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes. 1989; 38:1207-1210.
32. Zager RA, Johnson AC, Hanson SY, Shah VO. Acute tubular injury causes dysregulation of cellular cholesterol transport proteins. Am J Pathol. 2003;163:313-320.
33. Johnson AC, Yabu JM, Hanson S, Shah VO, Zager RA. Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression. Am J Pathol. 2003;162:283-291.
34. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res. 2002;55:870-876.
35. Sambhi MP, Swaminathan N, Wang H, Rong H. Increased EGF binding and EGFR mRNA expression in rat aorta with chronic administration of presser angiotensin II. Biochem Med Metab Biol. 1992;48:8-18.
36. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther. 1995;273:509-515.